151. Current Immunotherapeutic Efforts and Future Prospects in Human HIV Disease
- Author
-
John W. Hadden
- Subjects
Arc (protein) ,business.industry ,T cell ,Interleukin ,medicine.disease ,medicine.anatomical_structure ,Acquired immunodeficiency syndrome (AIDS) ,Immunology ,Medicine ,Thymopentin ,Sarcoma ,business ,Hiv disease ,Hormone ,medicine.drug - Abstract
Therapy trials have demonstrated efficacy of α interferon in AIDS with Kaposi Sarcoma; have strongly suggested efficacy of DTC and isoprinosine in ARC; and are suggestive for efficacy of imreg, ampligen, thymopentin, and thymostimulin in ARC. Many other substances are under evaluation. No immunotherapeutic agent has been useful in AIDS with opportunistic infections, although many combined trials with AZT are beginning. The preclinical and clinical data indicate that without the presence of a functioning thymus, new T cells cannot be produced thus immunorestorative treatments with thymomimetic biologicals (thymic hormones and IL2) or drugs (DTC and isoprinosine) in HIV disease should be administered prior to the thymic destruction characteristic of AIDS. Combinations of agents may be useful. New agents and strategies may derive from recent data indicating that interleukins and pituitary-derived hormones and factors play a critical role in T cell and thymus development.
- Published
- 1989